Adicet Bio (LTS:0HX7) Additional Paid-In Capital : $667.58 Mil(As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Additional Paid-In Capital?

Adicet Bio's quarterly additional paid-in capital increased from Sep. 2023 ($545.96 Mil) to Dec. 2023 ($550.94 Mil) and increased from Dec. 2023 ($550.94 Mil) to Mar. 2024 ($667.58 Mil).

Adicet Bio's annual additional paid-in capital increased from Dec. 2021 ($471.45 Mil) to Dec. 2022 ($530.45 Mil) and increased from Dec. 2022 ($530.45 Mil) to Dec. 2023 ($550.94 Mil).

Adicet Bio Additional Paid-In Capital Historical Data

The historical data trend for Adicet Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Additional Paid-In Capital Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

9.26

216.13

471.45

530.45

550.94

Adicet Bio Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															535.21	540.46	545.96	550.94	667.58

Adicet Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Adicet Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio (LTS:0HX7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (LTS:0HX7) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ACET:USA 1IJA:Germany

Address

200 Clarendon Street, Floor 6, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (LTS:0HX7) Headlines

No Headlines